JP2017529396A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529396A5 JP2017529396A5 JP2017534526A JP2017534526A JP2017529396A5 JP 2017529396 A5 JP2017529396 A5 JP 2017529396A5 JP 2017534526 A JP2017534526 A JP 2017534526A JP 2017534526 A JP2017534526 A JP 2017534526A JP 2017529396 A5 JP2017529396 A5 JP 2017529396A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pif peptide
- composition
- cells
- transplantation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010022347 proteolysis-inducing peptide Proteins 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 41
- 238000002054 transplantation Methods 0.000 claims description 40
- 210000001519 tissue Anatomy 0.000 claims description 30
- 210000000056 organ Anatomy 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 27
- 208000001395 Acute radiation syndrome Diseases 0.000 claims description 23
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 210000004153 islets of langerhan Anatomy 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 210000002798 bone marrow cell Anatomy 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 6
- 231100000569 acute exposure Toxicity 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000010322 bone marrow transplantation Methods 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 230000000366 juvenile effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 80
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 230000001919 adrenal effect Effects 0.000 description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 9
- 210000002064 heart cell Anatomy 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 231100000636 lethal dose Toxicity 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 208000020576 Adrenal disease Diseases 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051077P | 2014-09-16 | 2014-09-16 | |
| US62/051,077 | 2014-09-16 | ||
| US201562113298P | 2015-02-06 | 2015-02-06 | |
| US62/113,298 | 2015-02-06 | ||
| US201562211660P | 2015-08-28 | 2015-08-28 | |
| US62/211,660 | 2015-08-28 | ||
| PCT/US2015/050532 WO2016044493A1 (en) | 2014-09-16 | 2015-09-16 | Compositions and methods for treating acute radiation syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201734A Division JP2021046432A (ja) | 2014-09-16 | 2020-12-04 | 急性放射線症候群を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529396A JP2017529396A (ja) | 2017-10-05 |
| JP2017529396A5 true JP2017529396A5 (enExample) | 2018-11-01 |
| JP6806685B2 JP6806685B2 (ja) | 2021-01-06 |
Family
ID=55533820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534526A Active JP6806685B2 (ja) | 2014-09-16 | 2015-09-16 | 急性放射線症候群を治療するための組成物及び方法 |
| JP2020201734A Pending JP2021046432A (ja) | 2014-09-16 | 2020-12-04 | 急性放射線症候群を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201734A Pending JP2021046432A (ja) | 2014-09-16 | 2020-12-04 | 急性放射線症候群を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20170319645A1 (enExample) |
| EP (1) | EP3193903A4 (enExample) |
| JP (2) | JP6806685B2 (enExample) |
| CN (1) | CN106999534A (enExample) |
| AU (3) | AU2015317771A1 (enExample) |
| CA (1) | CA2961375A1 (enExample) |
| IL (2) | IL295025A (enExample) |
| WO (1) | WO2016044493A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3341739A4 (en) | 2015-08-28 | 2019-07-10 | BioIncept LLC | MUTATED PEPTIDES AND METHOD FOR TREATING SUBJECTS THEREWITH |
| CA2996874A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
| WO2018156801A2 (en) * | 2017-02-22 | 2018-08-30 | Bioincept, Llc | Peptides and methods of treating dystrophy-related disorders using the same |
| AU2018304200A1 (en) * | 2017-07-17 | 2020-02-13 | Bioincept, Llc | Peptides and methods of transplantation and restorative organ function |
| WO2022047196A1 (en) | 2020-08-28 | 2022-03-03 | Nisibis, Llc-S | Pten inhibitors for treatment and prevention of bone marrow loss |
| WO2023056075A1 (en) * | 2021-10-01 | 2023-04-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors |
| EP4248985A1 (en) * | 2022-03-25 | 2023-09-27 | Consejo Superior de Investigaciones Científicas (CSIC) | Peptides for the treatment of retinitis pigmentosa |
| WO2025117717A1 (en) * | 2023-11-27 | 2025-06-05 | The Brigham And Women’S Hospital, Inc. | Skin based test for detection of radiation exposure |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4629722A (en) * | 1984-07-12 | 1986-12-16 | Ribi Immunochem Research, Inc. | Method of inhibiting the onset of acute radiation syndrome |
| NZ547139A (en) * | 2003-10-22 | 2009-12-24 | Bioincept Llc | Use of preimplantation factor peptides to treat intolerence to embryo implantation |
| US7723290B2 (en) * | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
| EP2680872B1 (en) * | 2011-03-02 | 2018-08-15 | BioIncept LLC | Use of pif peptides for treating infections, atherosclerosis and peritonitis |
| MX365403B (es) * | 2012-01-09 | 2019-05-31 | Serpin Pharma Llc | Peptidos y metodos para usarlos. |
| US20160263186A1 (en) * | 2013-10-22 | 2016-09-15 | Bioincept, Llc | Pif-transfected cells and methods of use |
-
2015
- 2015-09-16 AU AU2015317771A patent/AU2015317771A1/en not_active Abandoned
- 2015-09-16 WO PCT/US2015/050532 patent/WO2016044493A1/en not_active Ceased
- 2015-09-16 US US15/512,001 patent/US20170319645A1/en not_active Abandoned
- 2015-09-16 EP EP15842062.0A patent/EP3193903A4/en not_active Withdrawn
- 2015-09-16 IL IL295025A patent/IL295025A/en unknown
- 2015-09-16 JP JP2017534526A patent/JP6806685B2/ja active Active
- 2015-09-16 CA CA2961375A patent/CA2961375A1/en not_active Abandoned
- 2015-09-16 IL IL251108A patent/IL251108B/en unknown
- 2015-09-16 CN CN201580061796.4A patent/CN106999534A/zh active Pending
-
2019
- 2019-04-18 AU AU2019202741A patent/AU2019202741A1/en not_active Abandoned
-
2020
- 2020-12-04 JP JP2020201734A patent/JP2021046432A/ja active Pending
-
2021
- 2021-04-16 AU AU2021202310A patent/AU2021202310A1/en not_active Abandoned
- 2021-09-10 US US17/472,574 patent/US20220249595A1/en not_active Abandoned
-
2024
- 2024-05-31 US US18/731,133 patent/US12458681B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529396A5 (enExample) | ||
| Lee et al. | Heme oxygenase‐1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells | |
| Kim et al. | Comparison of four pancreatic islet implantation sites | |
| CN102083426A (zh) | 与非大麻素化学治疗剂(例如血清或者烷基化剂)相组合的大麻素 | |
| KR20150065881A (ko) | 암 표적화 치료 및 암 재발 예방을 위한 헤모글로빈 기반 산소운반체 함유 약학적 조성물 | |
| JP2018520090A5 (enExample) | ||
| JP2016509050A5 (enExample) | ||
| RU2014124171A (ru) | Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе | |
| JP2020531529A5 (enExample) | ||
| Frias Neto et al. | Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats | |
| JP2017535546A (ja) | 新規な方法 | |
| CN114732807A (zh) | 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用 | |
| Lonyai et al. | The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases | |
| KR102712578B1 (ko) | 혈관화 조직을 유전적으로 변형시키는 방법 | |
| Monbaliu et al. | Liver transplantation using non-heart-beating donors: Belgian experience | |
| US20210353767A1 (en) | Compositions and methods for drug delivery | |
| Jung et al. | Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen | |
| AU2017376704A1 (en) | Composition, application thereof and treatment method | |
| Hawthorne et al. | Outcomes for islet transplantation in donation after circulatory death compared with donation after brain death in Australia | |
| TWI889188B (zh) | 母帕司汀（Muparfostat）用於製備治療胰臟癌之醫藥組成物的用途 | |
| TWI731944B (zh) | 移植病患之治療 | |
| Gruchet et al. | Pomalidomide 3rd line versus 4th line for in Early Relapsed Refractory Multiple Myeloma | |
| Dajani et al. | Treating diabetes with islet cell transplantation: lessons from the Edmonton experience | |
| Tretyak et al. | Long-term preservation of vitality of xenogenic thyrocytes in the recipient after their transplantation into the blood stream | |
| Pathak et al. | Delivery of Pancreatic Islets and Single Dose Local Immune Suppression Into Subcutaneous Space Using Injectable Hydrogel Provides Indefinite Survival of the Graft in Mouse Model of Diabetes |